Trastuzumab Deruxtecan: First Approval
Trastuzumab deruxtecan (ENHERTU ® ), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2020-04, Vol.80 (5), p.501-508 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 508 |
|---|---|
| container_issue | 5 |
| container_start_page | 501 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 80 |
| creator | Keam, Susan J. |
| description | Trastuzumab deruxtecan (ENHERTU
®
), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval. |
| doi_str_mv | 10.1007/s40265-020-01281-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2384155118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2384155118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-5b4d3fc42f587a537b7da033e238601058abe5c11ebf428e51c7115d5543b3163</originalsourceid><addsrcrecordid>eNp9kEtLAzEQx4Motj6-gAcpCN6iM0lms-utVKtCwUs9h2Q3Ky19meyK-ulN3ao3T8PM_B_wY-wM4QoB9HVUIDLiIIADihy52mN9RF1wLAj2WR_SmWdZpnvsKMb5di2oOGQ9KVApjUWfXU6DjU372S6tG9z60L43vrSrm8F4FmIzGG42Yf1mFyfsoLaL6E9385g9j--mowc-ebp_HA0nvJSaGk5OVbIulagp15akdrqyIKUXMs8AgXLrPJWI3tVK5J6w1IhUESnpJGbymF10uan2tfWxMfN1G1ap0qQIhUSIeVKJTlWGdYzB12YTZksbPgyC2aIxHRqT0JhvNEYl0_kuunVLX_1aflgkgewEMb1WLz78df8T-wWk_mwf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2384155118</pqid></control><display><type>article</type><title>Trastuzumab Deruxtecan: First Approval</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Keam, Susan J.</creator><creatorcontrib>Keam, Susan J.</creatorcontrib><description>Trastuzumab deruxtecan (ENHERTU
®
), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-020-01281-4</identifier><identifier>PMID: 32144719</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>AdisInsight Report ; Agreements ; Antibodies ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Breast cancer ; Camptothecin - analogs & derivatives ; Camptothecin - chemistry ; Camptothecin - pharmacology ; Cell cycle ; Clinical trials ; Collaboration ; Colorectal cancer ; Colorectal carcinoma ; Deoxyribonucleic acid ; DNA ; DNA topoisomerase ; DNA Topoisomerases, Type I - metabolism ; Drug Approval ; Drug dosages ; Enzymes ; ErbB-2 protein ; Gastric cancer ; Humans ; Immunoconjugates - chemistry ; Immunoconjugates - pharmacology ; Immunotherapy ; Internal Medicine ; Lung cancer ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Monoclonal antibodies ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Non-small cell lung carcinoma ; Patients ; Pharmacology/Toxicology ; Pharmacotherapy ; Phosphorylation ; Small cell lung carcinoma ; Solid tumors ; Targeted cancer therapy ; Topoisomerase I Inhibitors - chemistry ; Topoisomerase I Inhibitors - pharmacology ; Trastuzumab ; Trastuzumab - chemistry ; Trastuzumab - pharmacology ; Tumors</subject><ispartof>Drugs (New York, N.Y.), 2020-04, Vol.80 (5), p.501-508</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Copyright Springer Nature B.V. Apr 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-5b4d3fc42f587a537b7da033e238601058abe5c11ebf428e51c7115d5543b3163</citedby><cites>FETCH-LOGICAL-c375t-5b4d3fc42f587a537b7da033e238601058abe5c11ebf428e51c7115d5543b3163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-020-01281-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-020-01281-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32144719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keam, Susan J.</creatorcontrib><title>Trastuzumab Deruxtecan: First Approval</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Trastuzumab deruxtecan (ENHERTU
®
), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.</description><subject>AdisInsight Report</subject><subject>Agreements</subject><subject>Antibodies</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Breast cancer</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - chemistry</subject><subject>Camptothecin - pharmacology</subject><subject>Cell cycle</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA topoisomerase</subject><subject>DNA Topoisomerases, Type I - metabolism</subject><subject>Drug Approval</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>ErbB-2 protein</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Immunoconjugates - chemistry</subject><subject>Immunoconjugates - pharmacology</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Phosphorylation</subject><subject>Small cell lung carcinoma</subject><subject>Solid tumors</subject><subject>Targeted cancer therapy</subject><subject>Topoisomerase I Inhibitors - chemistry</subject><subject>Topoisomerase I Inhibitors - pharmacology</subject><subject>Trastuzumab</subject><subject>Trastuzumab - chemistry</subject><subject>Trastuzumab - pharmacology</subject><subject>Tumors</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLAzEQx4Motj6-gAcpCN6iM0lms-utVKtCwUs9h2Q3Ky19meyK-ulN3ao3T8PM_B_wY-wM4QoB9HVUIDLiIIADihy52mN9RF1wLAj2WR_SmWdZpnvsKMb5di2oOGQ9KVApjUWfXU6DjU372S6tG9z60L43vrSrm8F4FmIzGG42Yf1mFyfsoLaL6E9385g9j--mowc-ebp_HA0nvJSaGk5OVbIulagp15akdrqyIKUXMs8AgXLrPJWI3tVK5J6w1IhUESnpJGbymF10uan2tfWxMfN1G1ap0qQIhUSIeVKJTlWGdYzB12YTZksbPgyC2aIxHRqT0JhvNEYl0_kuunVLX_1aflgkgewEMb1WLz78df8T-wWk_mwf</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Keam, Susan J.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200401</creationdate><title>Trastuzumab Deruxtecan: First Approval</title><author>Keam, Susan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-5b4d3fc42f587a537b7da033e238601058abe5c11ebf428e51c7115d5543b3163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>AdisInsight Report</topic><topic>Agreements</topic><topic>Antibodies</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Breast cancer</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - chemistry</topic><topic>Camptothecin - pharmacology</topic><topic>Cell cycle</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA topoisomerase</topic><topic>DNA Topoisomerases, Type I - metabolism</topic><topic>Drug Approval</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>ErbB-2 protein</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Immunoconjugates - chemistry</topic><topic>Immunoconjugates - pharmacology</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Phosphorylation</topic><topic>Small cell lung carcinoma</topic><topic>Solid tumors</topic><topic>Targeted cancer therapy</topic><topic>Topoisomerase I Inhibitors - chemistry</topic><topic>Topoisomerase I Inhibitors - pharmacology</topic><topic>Trastuzumab</topic><topic>Trastuzumab - chemistry</topic><topic>Trastuzumab - pharmacology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keam, Susan J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keam, Susan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trastuzumab Deruxtecan: First Approval</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>80</volume><issue>5</issue><spage>501</spage><epage>508</epage><pages>501-508</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Trastuzumab deruxtecan (ENHERTU
®
), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32144719</pmid><doi>10.1007/s40265-020-01281-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2020-04, Vol.80 (5), p.501-508 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_journals_2384155118 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | AdisInsight Report Agreements Antibodies Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Breast cancer Camptothecin - analogs & derivatives Camptothecin - chemistry Camptothecin - pharmacology Cell cycle Clinical trials Collaboration Colorectal cancer Colorectal carcinoma Deoxyribonucleic acid DNA DNA topoisomerase DNA Topoisomerases, Type I - metabolism Drug Approval Drug dosages Enzymes ErbB-2 protein Gastric cancer Humans Immunoconjugates - chemistry Immunoconjugates - pharmacology Immunotherapy Internal Medicine Lung cancer Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Neoplasms - drug therapy Neoplasms - metabolism Non-small cell lung carcinoma Patients Pharmacology/Toxicology Pharmacotherapy Phosphorylation Small cell lung carcinoma Solid tumors Targeted cancer therapy Topoisomerase I Inhibitors - chemistry Topoisomerase I Inhibitors - pharmacology Trastuzumab Trastuzumab - chemistry Trastuzumab - pharmacology Tumors |
| title | Trastuzumab Deruxtecan: First Approval |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T22%3A36%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trastuzumab%20Deruxtecan:%20First%20Approval&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Keam,%20Susan%20J.&rft.date=2020-04-01&rft.volume=80&rft.issue=5&rft.spage=501&rft.epage=508&rft.pages=501-508&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-020-01281-4&rft_dat=%3Cproquest_cross%3E2384155118%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2384155118&rft_id=info:pmid/32144719&rfr_iscdi=true |